KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Liabilities and Shareholders Equity (2016 - 2025)

Pacira BioSciences (PCRX) has 16 years of Liabilities and Shareholders Equity data on record, last reported at $1.3 billion in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity fell 18.58% year-over-year to $1.3 billion; the TTM value through Dec 2025 reached $5.7 billion, down 9.82%, while the annual FY2025 figure was $1.3 billion, 18.58% down from the prior year.
  • Liabilities and Shareholders Equity reached $1.3 billion in Q4 2025 per PCRX's latest filing, down from $1.3 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.1 billion in Q4 2021 and bottomed at $1.3 billion in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $1.6 billion, with a median of $1.5 billion recorded in 2023.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 62.83% in 2021, then decreased 19.46% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $2.1 billion in 2021, then decreased by 18.99% to $1.7 billion in 2022, then dropped by 6.35% to $1.6 billion in 2023, then decreased by 1.33% to $1.6 billion in 2024, then fell by 18.58% to $1.3 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $1.3 billion in Q4 2025, $1.3 billion in Q3 2025, and $1.5 billion in Q2 2025.